Dual-specificity phosphatase 6 plays a critical role in the maintenance of a cancer stem-like cell phenotype in human endometrial cancer

1.

2.

Molecular Cancer Biology

3.

4.

5.

6.

7.

8.

9.

10.

11.

12.

13.

14.

15.

16.

Ferlay J, Colombet M, Soerjomataram I, et al.

Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods.

Int J Cancer 2019;144:1941–53.

Van Nyen T, Moiola CP, Colas E, et al. Modeling

endometrial cancer: past, present, and future. Int J

Mol Sci 2018;19:2348.

Morice P, Leary A, Creutzberg C, et al. Endometrial cancer. Lancet 2016;387:1094–108.

Dawood S, Austin L, Cristofanilli M. Cancer stem

cells: implications for cancer therapy. Oncology

(Williston Park) 2014;28:1101–7.

Kreso A, Dick JE. Evolution of the cancer stem

cell model. Cell Stem Cell 2014;14:275–91.

Salgia R, Kulkarni P. The genetic/non-genetic

duality of drug ’Resistance’ in cancer. Trends Cancer 2018;4:110–8.

Vander Linden C, Corbet C. Therapeutic targeting

of cancer stem cells: integrating and exploiting the

acidic niche. Front Oncol 2019;9:159.

Al-Hajj M, Wicha MS, Benito-Hernandez A, et al.

Prospective identification of tumorigenic breast

cancer cells. Proc Natl Acad Sci USA 2003;100:

3983–8.

Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates

from a primitive hematopoietic cell. Nat Med

1997;3:730–7.

Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994;367:

645–8.

Vescovi AL, Galli R, Reynolds BA. Brain tumour

stem cells. Nat Rev Cancer 2006;6:425–36.

Hubbard SA, Friel AM, Kumar B, et al. Evidence

for cancer stem cells in human endometrial carcinoma. Cancer Res 2009;69:8241–8.

Kato K, Takao T, Kuboyama A, et al. Endometrial

cancer side-population cells show prominent

migration and have a potential to differentiate

into the mesenchymal cell lineage. Am J Pathol

2010;176:381–92.

Kato K, Kuhara A, Yoneda T, et al. Sodium butyrate

inhibits the self-renewal capacity of endometrial

tumor side-population cells by inducing a DNA

damage response. Mol Cancer Ther 2011;10:1430–9.

Kusunoki S, Kato K, Tabu K, et al. The inhibitory effect of salinomycin on the proliferation,

migration and invasion of human endometrial

cancer stem-like cells. Gynecol Oncol 2013;129:

598–605.

Boulding T, Wu F, McCuaig R, et al. Differential

roles for DUSP family members in epithelial-tomesenchymal transition and cancer stem cell regulation in breast cancer. PLoS One 2016;11:

e0148065.

17. Ahmad MK, Abdollah NA, Shafie NH, et al.

Dual-specificity phosphatase 6 (DUSP6): a review

of its molecular characteristics and clinical relevance in cancer. Cancer Biol Med 2018;15:14–28.

18. Degl’Innocenti D, Romeo P, Tarantino E, et al.

DUSP6/MKP3 is overexpressed in papillary and

poorly differentiated thyroid carcinoma and contributes to neoplastic properties of thyroid cancer

cells. Endocr Relat Cancer 2013;20:23–37.

19. Lee JU, Huang S, Lee MH, et al. Dual specificity

phosphatase 6 as a predictor of invasiveness in

papillary thyroid cancer. Eur J Endocrinol 2012;

167:93–101.

20. Li W, Song L, Ritchie AM, et al. Increased levels

of DUSP6 phosphatase stimulate tumourigenesis

in a molecularly distinct melanoma subtype. Pigment Cell Melanoma Res 2012;25:188–99.

21. Messina S, Frati L, Leonetti C, et al. Dualspecificity phosphatase DUSP6 has tumorpromoting properties in human glioblastomas.

Oncogene 2011;30:3813–20.

22. Wu F, McCuaig RD, Sutton CR, et al. Nuclearbiased DUSP6 expression is associated with cancer

spreading including brain metastasis in triplenegative breast cancer. Int J Mol Sci 2019;20:3080.

23. Yang B, Tan Y, Sun H, et al. Higher intratumor

than peritumor expression of DUSP6/MKP-3 is

associated with recurrence after curative resection of hepatocellular carcinoma. Chin Med J

(Engl) 2014;127:1211–7.

24. Farooq A, Chaturvedi G, Mujtaba S, et al. Solution structure of ERK2 binding domain of MAPK

phosphatase MKP-3: structural insights into

MKP-3 activation by ERK2. Mol Cell 2001;7:

387–99.

25. Muda M, Theodosiou A, Rodrigues N, et al. The

dual specificity phosphatases M3/6 and MKP-3

are highly selective for inactivation of distinct

mitogen-activated protein kinases. J Biol Chem

1996;271:27205–8.

26. Zeliadt NA, Mauro LJ, Wattenberg EV. Reciprocal

regulation of extracellular signal regulated kinase

1/2 and mitogen activated protein kinase

phosphatase-3. Toxicol Appl Pharmacol 2008;232:

408–17.

27. Yagi H, Asanoma K, Ohgami T, et al. GEP oncogene promotes cell proliferation through YAP

activation in ovarian cancer. Oncogene 2016;35:

4471–80.

28. Zhou L, Sheng D, Wang D, et al. Identification of

cancer-type specific expression patterns for active

aldehyde dehydrogenase (ALDH) isoforms in

ALDEFLUOR assay. Cell Biol Toxicol 2019;35:

161–77.

29. Li L, Bhatia R. Stem cell quiescence. Clin Cancer

Res 2011;17:4936–41.

30. Yusuf N, Inagaki T, Kusunoki S, et al. SPARC was

overexpressed in human endometrial cancer stemlike cells and promoted migration activity.

Gynecol Oncol 2014;134:356–63.

31. Lee E, Yang J, Ku M, et al. Metabolic stress

induces a Wnt-dependent cancer stem cell-like

state transition. Cell Death Dis 2015;6:e1805.

32. Kodaki T, Woscholski R, Hallberg B, et al. The

activation of phosphatidylinositol 3-kinase by Ras.

Curr Biol 1994;4:798–806.

33. Suire S, Hawkins P, Stephens L. Activation of

phosphoinositide 3-kinase gamma by Ras. Curr

Biol 2002;12:1068–75.

34. Moriishi T, Kawai Y, Komori H, et al. Bcl2 deficiency activates FoxO through Akt inactivation

and accelerates osteoblast differentiation. PLoS

One 2014;9:e86629.

35. Chang L, Graham PH, Hao J, et al. Acquisition of

epithelial-mesenchymal transition and cancer

stem cell phenotypes is associated with activation

of the PI3K/Akt/mTOR pathway in prostate cancer radioresistance. Cell Death Dis 2013;4:e875.

36. Dong P, Konno Y, Watari H, et al. The impact of

microRNA-mediated PI3K/AKT signaling on

epithelial-mesenchymal transition and cancer

stemness in endometrial cancer. J Transl Med 2014;

12:231.

37. Singh RK, Dhadve A, Sakpal A, et al. An active

IGF-1R-AKT signaling imparts functional heterogeneity in ovarian CSC population. Sci Rep 2016;6:

36612.

38. Xia P, Xu XY. PI3K/Akt/mTOR signaling pathway

in cancer stem cells: from basic research to clinical

application. Am J Cancer Res 2015;5:1602–9.

39. Ninomiya Y, Kato K, Takahashi A, et al. K-Ras

and H-Ras activation promote distinct consequences on endometrial cell survival. Cancer Res

2004;64:2759–65.

40. Mendoza MC, Er EE, Blenis J. The Ras-ERK and

PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem Sci 2011;36:320–8.

41. Moelling K, Schad K, Bosse M, et al. Regulation of

Raf-Akt cross-talk. J Biol Chem 2002;277:31099–106.

42. Zimmermann S, Moelling K. Phosphorylation and

regulation of Raf by Akt (protein kinase B). Science 1999;286:1741–4.

43. Arkun Y. Dynamic modeling and analysis of the

cross-talk between insulin/AKT and

MAPK/ERK signaling pathways. PLoS One

2016;11:e0149684.

44. Son B, Lee S, Youn H, et al. The role of tumor

microenvironment in therapeutic resistance.

Oncotarget 2017;8:3933–45.

45. Correia AL, Bissell MJ. The tumor microenvironment is a dominant force in multidrug resistance.

Drug Resist Updat 2012;15:39–49.

Int. J. Cancer: 147, 1987–1999 (2020) © 2020 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf

of UICC

1999

Kato et al.

48. Pastushenko I, Brisebarre A, Sifrim A, et al. Identification of the tumour transition states occurring

during EMT. Nature 2018;556:463–8.

49. Fan MJ, Liang SM, He PJ, et al. Dusp6 inhibits

epithelial-mesenchymal transition in endometrial

adenocarcinoma via ERK signaling pathway.

Radiol Oncol 2019;53:307–15.

50. Weigelt B, Warne PH, Lambros MB, et al. PI3K

pathway dependencies in endometrioid endometrial

cancer cell lines. Clin Cancer Res 2013;19:3533–44.

51. Unni AM, Harbourne B, Oh MH, et al.

Hyperactivation of ERK by multiple mechanisms

is toxic to RTK-RAS mutation-driven lung adenocarcinoma cells. Elife 2018;7:e33718.

Molecular Cancer Biology

46. Jordan NV, Johnson GL, Abell AN. Tracking the

intermediate stages of epithelial-mesenchymal

transition in epithelial stem cells and cancer. Cell

Cycle 2011;10:2865–73.

47. Pastushenko I, Blanpain C. EMT transition states

during tumor progression and metastasis. Trends

Cell Biol 2019;29:212–26.

Int. J. Cancer: 147, 1987–1999 (2020) © 2020 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf

of UICC

...